Drug Trial Radar · NCT03710564
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Last checked: Nov 20, 2026Latest source record: Jan 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
535
Actual
Start
Oct 30, 2018
Primary completion
Dec 21, 2020
Study completion Jul 1, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.
Conditions
- Age-Related Macular Degeneration
Interventions
BrolucizumabBiological
6 mg/0.05mL solution for intravitreal injection
AfliberceptBiological
2 mg/0.05mL solution for intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Week 52Time frame: Baseline, week 52
Locations
61 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
Huntington Beach, California
Novartis Investigative Site
Mountain View, California
Novartis Investigative Site
Oakland, California
Novartis Investigative Site
Oxnard, California
Novartis Investigative Site
Palo Alto, California
Novartis Investigative Site
Redlands, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Santa Barbara, California
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Golden, Colorado
Novartis Investigative Site
Deerfield Beach, Florida
Novartis Investigative Site
Fort Lauderdale, Florida
Novartis Investigative Site
Fort Myers, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Mt. Dora, Florida
Novartis Investigative Site
Pensacola, Florida
Novartis Investigative Site
St. Petersburg, Florida
Novartis Investigative Site
Stuart, Florida
Novartis Investigative Site
Marietta, Georgia
Novartis Investigative Site
‘Aiea, Hawaii
Novartis Investigative Site
Wheaton, Illinois
Novartis Investigative Site
West Des Moines, Iowa
Novartis Investigative Site
Lenexa, Kansas
Novartis Investigative Site
New Orleans, Louisiana
Novartis Investigative Site
West Monroe, Louisiana
Novartis Investigative Site
Waldorf, Maryland
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Springfield, Massachusetts
Novartis Investigative Site
Royal Oak, Michigan
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Las Vegas, Nevada
Novartis Investigative Site
Reno, Nevada
Novartis Investigative Site
Bloomfield, New Jersey
Novartis Investigative Site
Toms River, New Jersey
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.